| 85.727 2.177 (2.61%) | 05-13 15:07 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 105.28 |
1-year : | 122.97 |
| Resists | First : | 90.14 |
Second : | 105.28 |
| Pivot price | 84.16  |
|||
| Supports | First : | 82.41 |
Second : | 77.63 |
| MAs | MA(5) : | 84.79 |
MA(20) : | 85 |
| MA(100) : | 81.3 |
MA(250) : | 63.43 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 54.7 |
D(3) : | 56.3 |
| RSI | RSI(14): 52.5 |
|||
| 52-week | High : | 103 | Low : | 28.05 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KYMR ] has closed below upper band by 31.3%. Bollinger Bands are 45.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 84.31 - 84.83 | 84.83 - 85.2 |
| Low: | 80.65 - 81.31 | 81.31 - 81.77 |
| Close: | 82.68 - 83.65 | 83.65 - 84.34 |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Wed, 13 May 2026
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Tue, 12 May 2026
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) - PR Newswire
Mon, 11 May 2026
Kymera Therapeutics director Elena Ridloff sells $261,000 in stock By Investing.com - Investing.com Nigeria
Mon, 11 May 2026
KYMR (KYMR) Form 144: 3,000-share sale; prior 10b5-1 sales disclosed - Stock Titan
Thu, 07 May 2026
How The Kymera Therapeutics (KYMR) Story Is Shifting Around KT-621 And Degrader Potential - Yahoo Finance
Mon, 04 May 2026
Kymera Therapeutics, Inc. Rings the Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 82 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 109.6 (%) |
| Shares Short | 9,620 (K) |
| Shares Short P.Month | 9,970 (K) |
| EPS | -3.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.42 |
| Profit Margin | 0 % |
| Operating Margin | -244.9 % |
| Return on Assets (ttm) | -17.2 % |
| Return on Equity (ttm) | -27.1 % |
| Qtrly Rev. Growth | 55.5 % |
| Gross Profit (p.s.) | -3.23 |
| Sales Per Share | 0.62 |
| EBITDA (p.s.) | -4.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -243 (M) |
| Levered Free Cash Flow | -141 (M) |
| PE Ratio | -23.92 |
| PEG Ratio | 0 |
| Price to Book value | 4.4 |
| Price to Sales | 136.82 |
| Price to Cash Flow | -29.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|